Uppsala, Sweden

Andrew Pickett

This inventor holds 2 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignees: Ipsen Biopharm Limited, Galderma Holding Sa. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Pickett. Retrieved from https://idiyas.com/inventor/andrew-pickett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.5

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew Pickett

Introduction

Andrew Pickett is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of neurotoxin formulations. His work focuses on creating stable liquid formulations that are free of animal proteins, which have important therapeutic applications.

Latest Patents

Andrew Pickett holds a patent for a liquid neurotoxin formulation stabilized with tryptophan or tyrosine. This invention relates to stable liquid neurotoxin formulations that include a surfactant, an amino acid selected from tryptophan and tyrosine, and a buffer comprising sodium, chloride, and phosphate ions. The formulations have a pH between 5.5 and 8 and are stable for two months. These compositions are suitable for therapeutic use, particularly for administration to patients to achieve desired therapeutic or aesthetic effects. The invention also highlights the use of tryptophan and tyrosine to protect proteinaceous neurotoxins from degradation in liquid compositions that are free of animal-derived proteins.

Career Highlights

Throughout his career, Andrew has worked with prominent companies in the pharmaceutical industry. He has been associated with Ipsen Biopharm Limited and Galderma Holding SA, where he contributed to the development of innovative therapeutic solutions.

Collaborations

Andrew has collaborated with notable colleagues, including Anders Jarstad and Anna Friis. Their combined expertise has furthered advancements in the field of neurotoxin formulations.

Conclusion

Andrew Pickett's innovative work in developing stable liquid neurotoxin formulations has significant implications for therapeutic applications. His contributions continue to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…